Incyte analyst coverage
WebApr 12, 2024 · Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY) and COMPASS Pathways (CMPS) - Compass Pathways (NASDAQ:CMPS), Incyte (NASDAQ:INCY) - Benzinga Companies in... WebBased on analysts offering 12 month price targets for INCY in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .
Incyte analyst coverage
Did you know?
WebBased on 13 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $87.46 with a high forecast of $113.00 and a low forecast of $61.00 . The average price target represents a … WebJan 9, 2024 · JP MORGAN HEALTHCARE CONFERENCE JANUARY 9, 2024. Forward-looking statements. Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: expectations regarding 2024 newsflow items; the …
WebIncyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages,... WebApr 12, 2024 · For the last few months, analysts have been revising downwards their earnings forecast. Over the past twelve months, analysts' consensus has been significantly revised downwards. Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
WebNov 8, 2024 · Following the latest results, Incyte's 18 analysts are now forecasting revenues of US$2.86b in 2024. This would be a solid 16% improvement in sales compared to the last 12 months. WebApr 4, 2024 · Incyte had a net margin of 10.03% and a return on equity of 11.45%. The company had revenue of $926.70 million during the quarter, compared to analyst estimates of $880.25 million. During the same period last year, the business earned ($0.07) EPS. Incyte's quarterly revenue was up 7.4% compared to the same quarter last year.
WebApr 12, 2024 · -- Incyte has an average outperform rating and price target range of $61 to $118, according to analysts polled by Capital IQ. Price: 74.54, Change: +0.37, Percent Change: +0.50 ... April 12, 2024 ... Rankings Coverage. Screeners Stock Screener Home. Investment Themes. Ageing Population. Sin stocks. The SPAC ...
WebApr 10, 2024 · Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact' Mar. 24, 2024 at 11:28 a.m. ET on Benzinga.com Incyte (INCY) Gets CRL for Jakafi Extended ... fred nachmanWebFeb 9, 2024 · These 4 analysts have an average price target of $74.25 versus the current price of Incyte at $68.65, implying upside. Below is a summary of how these 4 analysts rated Incyte over the past 3 months. fred mystery machineWebAug 30, 2024 · Get the latest Incyte Corporation (INCY) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. ... News Profile Analyst Coverage 5 Yr. fred nachman chicagoWebMar 22, 2024 · Incyte (INCY) Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Incyte yesterday and set a price target of $76.00. The company’s shares closed last Tuesday at $73.49. fred nachtigalWebApr 10, 2024 · Based on 10 analyst s offering ratings for Incyte Corp. Buy Strong Buy 2 analysts 20% Buy 2 analysts 20% Hold 5 analysts 50% Sell 1 analysts 10% Strong Sell 0 analysts 0% Be the first to know when Wall Street analysts revise their INCY stock forecasts and price targets. Get Free INCY Updates INCY stock forecasts by analyst All Analysts … blink camera law enforcement contactWebMar 28, 2024 · According to 13 analyst offering 12-month price targets in the last 3 months, Incyte has an average price target of $94.23 with a high of $113.00 and a low of $60.00. fred naclerioWeb2 days ago · Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $87.46, which is a 17.7% upside from current levels. In a report issued on April 10, RBC Capital also downgraded ... fred nagel spectrum health